<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-07T20:37:12+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>刚刚！15 个仿制药获批，10 个仿制药通过一致性评价</title>
    <updated>2020-12-07T18:25:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/HCYCGxsrSSq_qSmNozetOA</id>
    <link href="https://mp.weixin.qq.com/s/HCYCGxsrSSq_qSmNozetOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖「阿达木单抗」获批上市</title>
    <updated>2020-12-07T18:25:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/5oynlcGKYM7WyrYc60jOmg</id>
    <link href="https://mp.weixin.qq.com/s/5oynlcGKYM7WyrYc60jOmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州/安进合作的「注射用倍林妥莫双抗」获批上市</title>
    <updated>2020-12-07T18:25:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/ym9FRGLHFolt1TywBUJriw</id>
    <link href="https://mp.weixin.qq.com/s/ym9FRGLHFolt1TywBUJriw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个 Bcl-2 抑制剂，艾伯维「维奈克拉片」获批上市</title>
    <updated>2020-12-07T18:25:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/NLFNhVKbe9z50-wlnpw9WA</id>
    <link href="https://mp.weixin.qq.com/s/NLFNhVKbe9z50-wlnpw9WA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【不容错过】2020药品上市后变更技术研究、申报策略及M4申报资料撰写专题培训</title>
    <updated>2020-12-07T18:25:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/t1IzbikxcJvkt_jwuIof3Q</id>
    <link href="https://mp.weixin.qq.com/s/t1IzbikxcJvkt_jwuIof3Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 年 11 月 CDE 药品审评报告</title>
    <updated>2020-12-04T19:07:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/fkx97jwmEIp0DFY5VadUGQ</id>
    <link href="https://mp.weixin.qq.com/s/fkx97jwmEIp0DFY5VadUGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>73 个品种符合第四批集采！涉及 128 家企业</title>
    <updated>2020-12-04T18:43:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/Le_zaD34LZOACdrwxRwzSA</id>
    <link href="https://mp.weixin.qq.com/s/Le_zaD34LZOACdrwxRwzSA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 4 款注射剂通过一致性评价，3 个为首家</title>
    <updated>2020-12-04T18:43:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/QobbyGiXObCmGaw-doIKCg</id>
    <link href="https://mp.weixin.qq.com/s/QobbyGiXObCmGaw-doIKCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>遗传性血管性水肿新药来了！「拉那芦人单抗」在国内获批</title>
    <updated>2020-12-04T18:43:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/hkPTkwQj6hjDeB2SS7cXJA</id>
    <link href="https://mp.weixin.qq.com/s/hkPTkwQj6hjDeB2SS7cXJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正大天晴乙肝 1 类新药启动临床</title>
    <updated>2020-12-04T18:43:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/BLK-Y7NhtuK-cW4T1HErBQ</id>
    <link href="https://mp.weixin.qq.com/s/BLK-Y7NhtuK-cW4T1HErBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>参会须知 | ICDC2020-第三届肿瘤免疫及伴随诊断合作峰会</title>
    <updated>2020-12-04T18:43:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/BFNraIr5PvcB6jjvc50hmg</id>
    <link href="https://mp.weixin.qq.com/s/BFNraIr5PvcB6jjvc50hmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>首个国产 PARP 抑制剂！恒瑞 1 类新药「氟唑帕利胶囊」即将获批</title>
    <updated>2020-12-03T18:03:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/MwU0ApY37aXo79YnkZMRCA</id>
    <link href="https://mp.weixin.qq.com/s/MwU0ApY37aXo79YnkZMRCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>海思科 1 类新药环泊酚即将获批</title>
    <updated>2020-12-03T18:03:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/KRSRGbl7KGB6JOZhwU5Iig</id>
    <link href="https://mp.weixin.qq.com/s/KRSRGbl7KGB6JOZhwU5Iig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>南京正大天晴「甲磺酸沙非胺片」首仿报上市</title>
    <updated>2020-12-03T18:03:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/-mK6Hd38YUdGQNd2VURKqw</id>
    <link href="https://mp.weixin.qq.com/s/-mK6Hd38YUdGQNd2VURKqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞「瑞马唑仑」第 3 个适应症报上市，2020 医保谈判进行中</title>
    <updated>2020-12-02T17:12:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/XXFxDzirdzVnPHHvO_kLuw</id>
    <link href="https://mp.weixin.qq.com/s/XXFxDzirdzVnPHHvO_kLuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 5 款仿制药通过一致性评价，3 个注射剂，2 个首家过评</title>
    <updated>2020-12-02T17:12:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/YcVhr_y-zI6BrceqCqyi_w</id>
    <link href="https://mp.weixin.qq.com/s/YcVhr_y-zI6BrceqCqyi_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>继续发力眼科领域，恒瑞干眼病新药 SHR8058 获批临床</title>
    <updated>2020-12-02T17:12:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/pQ1neu4vpWTUtOz4eV2fig</id>
    <link href="https://mp.weixin.qq.com/s/pQ1neu4vpWTUtOz4eV2fig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>潜在同类最佳，百济神州 Bcl-2 抑制剂获批临床</title>
    <updated>2020-12-02T17:12:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/wGkTQ9cKdRRuM-eXmeMnFA</id>
    <link href="https://mp.weixin.qq.com/s/wGkTQ9cKdRRuM-eXmeMnFA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第 32 批「通过一致性评价」名单来了</title>
    <updated>2020-12-01T18:00:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/HEpbIR6AIG2F0C7Ox-ET8Q</id>
    <link href="https://mp.weixin.qq.com/s/HEpbIR6AIG2F0C7Ox-ET8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>贝达药业「埃克替尼」术后辅助治疗新适应症即将开展临床数据核查</title>
    <updated>2020-12-01T18:00:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/Cr4L5nAAX4gXvVG-IiW0Xw</id>
    <link href="https://mp.weixin.qq.com/s/Cr4L5nAAX4gXvVG-IiW0Xw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>